Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 118

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 118
---
, and $1.5 million for the years ended December 31, 2024 and 2023, respectively. 

19. Commitments and Contingencies The following table summarizes the Company’s commitments to settle contractual obligations at December 31, 2024, other than leases which are recognized as operating lease liabilities in the consolidated balance sheet.  

        Year Ending December 31,

        (in thousands)

        2025
         
        $
        1,247

        2026

        163

        2027

        32

        2028

        40

        2029

        32

        Following years

        140

        Total
         
        $
        1,654

133

The commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. Collaboration and Research AgreementsCollaboration and research agreement obligations primarily relate to a strategic collaboration agreement that was entered into with the University of Texas M. D. Anderson Cancer Center (“MDACC”) in March 2020. The collaboration consists of preclinical studies and clinical trials designed by the Company and MDACC with the research to be completed by MDACC. The Company agreed to commit $10.0 million in funding for various studies over a period of five years, which has been fully paid as of December 31, 2024.The Company entered into an agreement with the Broad Institute, Inc. (“Broad”), in July 2022, under which Broad will perform specialty screening services at the Company’s request over the course of a three-year term in exchange for payments of $0.8 million per year, beginning in July 2022, totaling $2.3 million in the aggregate, which has been fully paid as of December 31, 2024.Purchase and Other ObligationsIn the normal course of business, the Company enters into contracts with Contract Research Organizations (“CROs”) and other third parties for preclinical studies and clinical trials, research and development supplies and other testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and provide for termination on 30 to 90 days’ prior written notice, and therefore are cancellable contracts. These payments are not included in the table above as the amount and timing of such payments are not known as of December